Abstract
Cancer stem cells (CSCs), which can self-renew and differentiate into different kinds of cancer cells, are suggested to be responsible for drug resistance and cancer relapse in a variety of cancer types. Researchers have outlined mechanisms by which CSCs display resistance to therapeutic agents, with the goal of developing agents, which target CSCs and improve treatment success rates and patient outcomes. In this chapter, the key role that CSCs play in various cancers has been outlined, alongside the different mechanisms in which they act by. This has resulted in recent breakthroughs in research, which has fortified the rationale to create agents which target CSCs. This novel strategy for the treatment of different types of cancer could lead to novel anticancer therapeutics which exhibit lower treatment resistance and relapse rates than before the discovery of CSCs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bailey SM, Murnane JP (2006) Telomeres, chromosome instability and cancer. Nucleic Acids Res 34:2408–2417
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Bruix J, Gores GJ, Mazzaferro V (2014) Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63(5):844–855. https://doi.org/10.1136/gutjnl-2013-306627. Epub 2014 Feb 14. PMID: 24531850; PMCID: PMC4337888
Butler SJ, Richardson L, Farias N, Morrison J, Coomber BL (2017) Characterization of cancer stem cell drug resistance in the human colorectal cancer cell lines HCT116 and SW480. Biochem Biophys Res Commun 490:29–35. https://doi.org/10.1016/j.bbrc.2017.05.176
Chen X, Rycaj K, Liu X, Tang DG (2013) New insights into prostate cancer stem cells. Cell Cycle 12:579–586
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17:313–319. [PubMed] [Google Scholar]
Cojoc M, Mäbert K, Muders MH, Dubrovska A (2015) A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol 31:16–27
Cozzi DA, Ceccanti S, Frediani S, Mele E, Cozzi F (2013) Renal function adaptation up to the fifth decade after treatment of children with unilateral renal tumor: a cross-sectional and longitudinal study. Pediatr Blood Cancer 60:1534–1538. https://doi.org/10.1002/pbc.24545
Deng Q, Tang DG (2015) Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr Relat Cancer 22:T209–T220
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A et al (2019) Breast cancer statistics. CA Cancer J Clin 69:438–451. https://doi.org/10.3322/caac.21583
Dey P, Rathod M, De A (2019) Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med Press) 11:115–135. https://doi.org/10.2147/BCTT.S189224
Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Di Santi A, Cernera G, Rossi V, Abbondanza C, Moncharmont B, Sinisi AA, Castoria G, Migliaccio A (2016) Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget 7(1):193–208. https://doi.org/10.18632/oncotarget.6220. PMID: 26506594; PMCID: PMC4807992
Eiro N, Gonzalez LO, Fraile M, Cid S, Schneider J, Vizoso FJ (2019) Breast cancer tumor stroma: cellular components, phenotypic heterogeneity, intercellular communication, prognostic implications and therapeutic opportunities. Cancer 11:11. https://doi.org/10.3390/cancers11050664
Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255
Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522–1533. https://doi.org/10.1158/0008-5472.can-03-3326
Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, Hornicek FJ, Amiji MM, Duan Z (2015) Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget 6:9313–9326
de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ, Jansen JH, Raymakers RA (2006) Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 20:750–754. https://doi.org/10.1038/sj.leu.2404131. [PubMed] [CrossRef] [Google Scholar
Guan Y, Gerhard B, Hogge DE (2003) Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101:3142–3149. https://doi.org/10.1182/blood-2002-10-3062. [PubMed] [CrossRef] [Google Scholar]
van Hagen P, Hulshof M, van Lanschot JJB, Steyerberg EW, Henegouwen MIV, Wijnhoven BPL et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
Han L, Kumar S, Fok JY, Tyagi AK, Mehta K (2014) Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor. Eur J Cancer 50(9):1685–1696
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322. https://doi.org/10.1016/j.ccr.2012.02.022. PMID: 22439926
Haraguchi N et al (2010) CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120(9):3326–3339. https://doi.org/10.1172/JCI42550
Harbeck N, Gnant M (2017) Breast cancer. Lancet 389:1134–1150. https://doi.org/10.1016/S0140-6736(16)31891-8
Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67:4827–4833
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726. https://doi.org/10.1038/nrc3599
Huang TH, Wu SY, Huang YJ, Wei PL, Wu AT, Chao TY (2017) The identification and validation of Trichosstatin a as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells. Am J Cancer Res 7:1227–1237
Ilmer M, Mazurek N, Byrd JC, Ramirez K, Hafley M, Alt E, Vykoukal J, Bresalier RS (2016) Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics. Cell Death Dis 7:e2337. https://doi.org/10.1038/cddis.2016.239. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Josefsson A, Linder A, Flondell Site D et al (2017) Circulating tumor cells as a marker for progression-free survival in metastatic castration-naïve prostate cancer. Prostate 77(8):849–858
Kenda Suster N, Virant-Klun I (2019) Presence and role of stem cells in ovarian cancer. World J Stem Cells 11(7):383–397. https://doi.org/10.4252/wjsc.v11.i7.383. PMID: 31396367; PMCID: PMC6682502
Kerr BA, Miocinovic S et al (2015) CD117+ cells in the circulation are predictive of advanced prostate cancer. Oncotarget 6(3):1889–1897
Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S et al (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47:570–584. https://doi.org/10.1016/j.molcel.2012.06.014
Koziel JE, Herbert BS (2015) The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2(+) breast cancer cells. Breast Cancer Res Treat 149:607–618
Kunze B, Wein F, Fang HY, Anand A, Baumeister T, Strangmann J et al (2020) Notch signaling mediates differentiation in barrett’s esophagus and promotes progression to adenocarcinoma. Gastroenterology 159:575–590. https://doi.org/10.1053/j.gastro.2020.04.033
Lagergren J, Smyth E, Cunningham D, Lagergren P (2017) Oesophageal cancer. Lancet 390:2383–2396
Lang SH, Frame FM, Collins AT (2009) Prostate cancer stem cells. J Pathol 217:299–306
Lee M, Nam EJ, Kim SW, Kim S, Kim JH, Kim YT (2012) Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. Int J Gynecol Cancer 22:1489–1496
Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO (2011) Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 53(1):160–170. https://doi.org/10.1002/hep.24000
Li F, Zhou K, Gao L, Zhang B, Li W, Yan W, Song X, Yu H, Wang S, Yu N, Jiang Q (2016) Radiation induces the generation of cancer stem cells: a novel mechanism for cancer radioresistance. Oncol Lett 12:3059–3065. https://doi.org/10.3892/ol.2016.5124
Li Y, Wang Z, Ajani JA et al (2021) Drug resistance and cancer stem cells. Cell Commun Signal 19:19. https://doi.org/10.1186/s12964-020-00627-5
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012) Management of HCC. J Hepatol 56(suppl 1):S75–S87
Liu H, Liu X, Zhang C, Zhu H, Xu Q, Bu Y, Lei Y (2017) Redox imbalance in the development of colorectal cancer. J Cancer 8:1586–1597
Lupia M, Cavallaro U (2017) Ovarian cancer stem cells: still an elusive entity? Mol Cancer 16:64
Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27(12):1749–1758
Ma S et al (2010) miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7(6):694–707. https://doi.org/10.1016/j.stem.2010.11.010
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O’Byrne KJ, Barr MP (2016) Lung cancer stem cells: the root of resistance. Cancer Lett 372(2):147–156. ISSN 0304-3835
Meurette O, Mehlen P (2018) Notch signaling in the tumor microenvironment. Cancer Cell 34(4):536–548. https://doi.org/10.1016/j.ccell.2018.07.009. Epub 2018 Aug 23. PMID: 30146333
Munakata K, Uemura M, Tanaka S, Kawai K, Kitahara T, Miyo M, Kano Y, Nishikawa S, Fukusumi T, Takahashi Y, Hata T, Nishimura J, Takemasa I et al (2016) Cancer stem-like properties in colorectal cancer cells with low proteasome activity. Clin Cancer Res 22:5277–5286. https://doi.org/10.1158/1078-0432.CCR-15-1945
Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133–143
Ozgul Ozdemir RB, Ozdemir AT, Oltulu F, Kurt K, Yigitturk G, Kirmaz C (2016) A comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues. Ann Diagn Pathol 25:60–63. https://doi.org/10.1016/j.anndiagpath.2016.09.012. [PubMed] [CrossRef] [Google Scholar]
Qin J, Liu X, Laffin B et al (2012) The PSA(−/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 10:556–569
Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423–1437. https://doi.org/10.1038/nm.3394. PMID: 24202395; PMCID: PMC3954707
Rebucci M, Michiels C (2013) Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85:1219–1226. https://doi.org/10.1016/j.bcp.2013.02.017
Rodriguez D, Ramkairsingh M, Lin X, Kapoor A, Major P, Tang D (2019) The central contributions of breast cancer stem cells in developing resistance to endocrine therapy in estrogen receptor (ER)-Positive breast cancer. Cancers (Basel) 11:1028. https://doi.org/10.3390/cancers11071028
Sarkar FH, Li Y, Wang Z, Kong D, Ali S (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy drug resist. Update 13:57–66
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551
Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751
Singh P, O’Connell M, Shubhashish S (2016) Epigenetic regulation of human DCLK-1 gene during colon-carcinogenesis: clinical and mechanistic implications. Stem Cell Investig 3:51
Siu MK, Wong ES, Kong DS, Chan HY, Jiang L, Wong OG, Lam EW, Chan KK, Ngan HY, Le XF, Cheung AN (2013) Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 32:3500–3509
Smalley M, Piggott L, Clarkson R (2013) Breast cancer stem cells: obstacles to therapy. Cancer Lett 338:57–62. https://doi.org/10.1016/j.canlet.2012.04.023
Stahl M, Kim TK, Zeidan AM (2016) Update on acute myeloid leukemia stem cells: new discoveries and therapeutic opportunities. World J Stem Cells. 8(10):316–331. https://doi.org/10.4252/wjsc.v8.i10.316. PMID: 27822339; PMCID: PMC5080639
Thol F, Ganser A (2020) Treatment of relapsed acute myeloid leukemia. Curr Treat Options in Oncol 21(8):66. https://doi.org/10.1007/s11864-020-00765-5. PMID: 32601974; PMCID: PMC7324428
Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441–1454. https://doi.org/10.1093/jnci/djm135. Epub 2007 Sep 25. PMID: 17895480
Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen SP et al (2012a) Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med 18:887–898
Wang L, Lu B, He M, Wang Y, Wang Z, Du L (2022) Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 10:811044. https://doi.org/10.3389/fpubh.2022.811044
Wang L, Simons DL, Lu X, Tu TY, Solomon S, Wang R, Rosario A, Avalos C, Schmolze D, Yim J, Waisman J, Lee PP (2019) Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat Immunol 20(9):1220–1230. https://doi.org/10.1038/s41590-019-0429-7. Epub 2019 Jul 8. PMID: 31285626; PMCID: PMC8802768
Wang X, Wang G, Zhao Y, Liu X, Ding Q, Shi J et al (2012b) STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res 26:325–335. https://doi.org/10.7555/JBR.26.20110050
Wang Z, Da Silva TG, Jin K, Han X, Ranganathan P, Zhu X et al (2014) Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res 74:6364–6374
Xu XL, Xing BC, Han HB, Zhao W, Hu MH, Xu ZL, Li JY, Xie Y, Gu J, Wang Y et al (2010) The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor. Carcinogenesis 31:167–174
Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, Stankiewicz E, Wang Y, Oliver RTD, Ahmad AS, Berney D, Shamash J, Lu YJ (2017) The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res 23(17):5112–5122. https://doi.org/10.1158/1078-0432.CCR-16-3081. Epub 2017 Jun 14. PMID: 28615267
Yamashita T, Wang XW (2013) Cancer stem cells in the development of liver cancer. J Clin Invest 123(5):1911–1918. https://doi.org/10.1172/JCI66024. Epub 2013 May 1. PMID: 23635789; PMCID: PMC3635728
Yang ZF et al (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13(2):153–166. https://doi.org/10.1016/j.ccr.2008.01.013
Zhang W, Liu Y, Sun N, Wang D, Boyd-Kirkup J, Dou X, Han JD (2013) Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep 4:542–553
Zheng Q, Zhang M, Zhou F, Zhang L, Meng X (2021) The breast cancer stem cells traits and drug resistance. Front Pharmacol 11:599965. https://doi.org/10.3389/fphar.2020.599965. PMID: 33584277; PMCID: PMC7876385
Zhou X, Li D, Wang X, Zhang B, Zhu H, Zhao J (2015) Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Oncotarget 6:3111–3122
Zhou S, Gravekamp C, Bermudes D, Liu K (2018) Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer 18(12):727–743. https://doi.org/10.1038/s41568-018-0070-z. PMID: 30405213; PMCID: PMC6902869
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Masoudi, M., Gopalan, V. (2023). Roles of Cancer Stem Cells in Therapy Resistance and Disease Recurrence. In: Islam, F., Lam, A.K. (eds) Cancer Stem Cells: Basic Concept and Therapeutic Implications. Springer, Singapore. https://doi.org/10.1007/978-981-99-3185-9_9
Download citation
DOI: https://doi.org/10.1007/978-981-99-3185-9_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-3184-2
Online ISBN: 978-981-99-3185-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)